<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721016</url>
  </required_header>
  <id_info>
    <org_study_id>MT10109L-005</org_study_id>
    <secondary_id>2014-005301-21</secondary_id>
    <nct_id>NCT03721016</nct_id>
  </id_info>
  <brief_title>MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL)
      with or without concurrent treatment of lateral canthal lines (LCL) in participants with
      moderate to severe GL and LCL.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of GL severity at maximum frown at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>The investigator and participant evaluates the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of GL treatment in participants who achieved a rating of ≥ 2-grade improvement from baseline in GL severity at maximum frown at Day 30 according to investigator assessments using the FWS</measure>
    <time_frame>Day 1 (first treatment) to Day 180</time_frame>
    <description>The investigator evaluates the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of responders for investigator assessments of GL severity at maximum frown using the FWS</measure>
    <time_frame>Day 30</time_frame>
    <description>The investigator evaluates the participant's GL severity using a 4-point scale (0 to 3) where 0=none and 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants reporting mostly satisfied/very satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) follow-up version Item 5 for GL</measure>
    <time_frame>Day 60</time_frame>
    <description>The Satisfaction Question 5 grades facial line treatment satisfaction on a 5-point scale (-2 to 2) where -2=Very dissatisfied and 2=Very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of responders for investigator assessments of GL severity at rest using the FWS</measure>
    <time_frame>Day 30</time_frame>
    <description>The investigator evaluates the participant's GL severity using a 4-point scale (0 to 3) where 0=none and 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who experienced an adverse event</measure>
    <time_frame>From Consent (Screening Visit) up to Day 420</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in vital signs</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Electrocardiogram (ECG) parameters</measure>
    <time_frame>Baseline to Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in lab parameters</measure>
    <time_frame>Screening to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with binding and neutralizing antibodies</measure>
    <time_frame>Day 360</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Glabellar Lines, Lateral Canthal Lines</condition>
  <arm_group>
    <arm_group_label>MT10109L Dose 1 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT10109L Dose 1 will be injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT10109L Dose 1 + MT10109L Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT10109L</intervention_name>
    <description>MT10109Lwill be injected into either the GL, LCL, or both.</description>
    <arm_group_label>MT10109L Dose 1 + MT10109L Dose 2</arm_group_label>
    <arm_group_label>MT10109L Dose 1 + Placebo</arm_group_label>
    <other_name>NivobotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be injected into either the GL, LCL, or both.</description>
    <arm_group_label>MT10109L Dose 1 + Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        • Female participants must not be pregnant or planning to get pregnant and willing to
        minimize the risk of inducing pregnancy for the duration of the clinical study and
        follow-up period.

        Exclusion Criteria

          -  Known immunization or hypersensitivity to any botulinum toxin serotype.

          -  Any medical condition that may put the participant at increased risk with exposure to
             MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic
             lateral sclerosis, or any other condition that might interfere with neuromuscular
             function.

          -  History of facial nerve palsy.

          -  Any uncontrolled systemic disease.

          -  Anticipated need for treatment with botulinum toxin of any serotype for any reason
             during the study (other than study intervention).

          -  Anticipated need for surgery or overnight hospitalization during the study.

          -  Prior exposure to botulinum toxin of any serotype for any reason.

          -  Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow
             lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery).

          -  Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg,
             Gore-Tex®), and/or autologous fat transplantation.

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study.

          -  Females who are pregnant, nursing, or planning a pregnancy during the study.

          -  Participants who plan for an extended absence away from the immediate area of the
             study site that would preclude them from returning for all protocol-specified study
             visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan-En Lin</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coleman Dermatologic Surgery Center</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser, Skin, &amp; Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkinDC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Clinical Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Skin MD</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sweat Clinics of Canada</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R 3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bertucci MedSpa Inc.</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L 8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Theatiner46</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Nordhessen</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis Dr. Hilton &amp; Partner</name>
      <address>
        <city>Düsseldorf</city>
        <state>NRW</state>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bermuda Practice</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Bosham Clinic</name>
      <address>
        <city>Chichester</city>
        <state>West Sussex</state>
        <zip>PO18 8AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

